Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin for adult patients suffering from metastatic or ...

This finding, he suggests, helps link the study of cell death in the worm and oncogenesis in people. "There were a number of papers that had suggested a relationship between cell death and oncogenesis ...

Libtayo works by attaching itself to a receptor called programmed cell death protein 1 (PD-1) on specific immune system cells called T cells.

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

A pioneering discovery at WEHI in 1988 of a protein that stopped programmed cell death sparked huge interest in the field, and has since led to a new drug to treat cancer.

Researchers at the University of Cologne have identified the key mitochondrial protein AIFM1 as a central coordinator of cellular energy production.